StockNews.AI
TELA
StockNews.AI
124 days

TELA Bio to Announce First Quarter 2025 Financial Results

1. TELA Bio to report Q1 2025 financial results on May 8, 2025. 2. A conference call will discuss the results and corporate update. 3. The company focuses on innovative soft-tissue reconstruction solutions. 4. Forward-looking statements may indicate potential growth but carry risks. 5. Investor details and registration required for the conference call.

Earnings
0%Current Return
VS
+0.01%S&P 500
$0.956204/17 04:15 PM EDTEvent Start
$0.956204/18 10:27 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report could influence investor sentiment but contains forward-looking risks without specific growth indications.

How important is it?

Earnings calls and updates are significant, potentially impacting investor confidence and stock value.

Why Short Term?

Investor reactions to financial results typically affect stock price within days, unlike long-term trends.

Related Companies

MDGLSMMC
April 17, 2025 16:05 ET  | Source: TELA Bio, Inc. MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A live webcast and replay can be accessed via the Events & Presentations page of the investor section of TELA's website. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com. Caution Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor ContactLouisa Smithir@telabio.com

Related News